FDA Adverse Event Injury Summary report: Y

SP 4.1MM RN, SLA 8MM, TI, LOXIM

MDR report key: 11209049 · Received January 21, 2021

Report

Report Number
0009613348-2021-05114
Event Type
Injury
Date Received
January 21, 2021
Date of Event
October 1, 2019
Report Date
January 21, 2021
Manufacturer
INSTITUT STRAUMANN AG
Product Code
DZE
UDI-DI
07630031719607
PMA / PMN Number
K033922
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
IN
Reporter Occupation
DENTIST

Narratives

Additional Manufacturer Narrative · 1

THE BATCH NUMBER COULD NOT BE VERIFIED DUE TO INCOMPLETE OR MISSING INFORMATION AND / OR PRODUCT FROM THE CUSTOMER. OUR MANUFACTURING Q-SYSTEM ASSURES THAT PRODUCTION AND PROCESS CONTROLS ARE IN PLACE TO ENSURE THAT BATCHES CONFIRM TO THE APPLICABLE SPECIFICATIONS BEFORE THEY ARE DISTRIBUTED. THE NON-INTEGRATION OF AN ENDOSSEOUS DENTAL IMPLANT DURING THE HEALING PHASE IS A KNOWN INHERENT RISK OF THE TREATMENT WITH DENTAL IMPLANTS. MOST IMPLANT FAILURES OCCUR BEFORE OCCLUSAL LOADING (ANALAINEN ET AL. 2013, KOLDSLAND ET AL. 2009). BASED ON CLINICAL STUDIES ABOUT 1-3% OF THE IMPLANTS FAIL WITHIN THE FIRST YEAR AFTER IMPLANTATION (GANELES ET AL. 2008). IMPLANTS MAY HAVE TO BE REMOVED IN CASE ONE OR MORE OF THE IMPLANT SUCCESS CRITERIA ARE NOT MET. IMPLANT SUCCESS CRITERIA ACCORDING TO BUSER ET AL. (1991) ARE: ABSENCE OF PERSISTENT SUBJECTIVE COMPLAINTS SUCH AS PAIN, FOREIGN BODY SENSATION AND /OR DYSESTHESIA, ABSENCE OF A RECURRENT PERI-IMPLANT INFECTION WITH SUPPURATION, ABSENCE OF IMPLANT MOBILITY, ABSENCE OF A CONTINUOUS RADIOLUCENCY AROUND THE IMPLANT. THE MANUFACTURER'S TREND ANALYSIS CONFIRMS THAT THE REPORTED EARLY FAILURE RATE ASSOCIATED WITH ITS DENTAL IMPLANTS IS BELOW THE EXPECTED FAILURE RATE FOR THIS TREATMENT AS PUBLISHED IN THE SCIENTIFIC LITERATURE. THIS COMPLAINT IS FOR A MAXGRAFT PROUCT FROM BOTISS. CAN YOU PLEASE DO THE PSO ASSESSMENT AND ALSO SEND THIS TO BOTISS SBA TODAY? THANKS

Description of Event or Problem · 1

THE CLINICIAN REPORTS THE IMPLANT WAS INSERTED (B)(6) 2019 IN THE PATIENT'S MOUTH. ON (B)(6) 2019, NON-OSSEOINTEGRATION WAS VERIFIED. PATIENT PRESENTED WITH BONE TYPE III. THE DEVICE WAS FORWARDED TO THE MANUFACTURER. AT THE EVENT THE PATIENT EXPERIENCED: MOBILITY. NO FURTHER PATIENT COMPLICATIONS WERE REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
104721 SP 4.1MM RN, SLA 8MM, TI, LOXIM ENDOSSEOUS DENTAL IMPLANT DZE INSTITUT STRAUMANN AG SLA Titanium TL 07630031719607

Patients

Seq Age Sex Outcome Treatment
1 40 YR Required Intervention